Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

  • In development
  • GID-TA11424
  • Expected publication date: 

The company have asked NICE to delay this appraisal so that they can incorporate additional data into their submission. NICE have agreed to this request. This appraisal will now be considered by the NICE Technology Appraisal Committee at a meeting on 4 November 2025.